MOWWOT, a company specializing in medical devices for intestinal transit disorder, and a member of CataloniaBio &  HealthTech, has announced the closure of the first tranche of its Series  A investment round worth 1.05 million euros. This first tranche has involved USM Global Corporation, an investment vehicle that brings together several crowdfunding investors from Capital Cell, ENISA, 4M Medical GmbH and other German business angels.

The company expects to close the second leg of the investment round in the next six  months. They are currently in talks with strategic investors, some of them through EIT Health and its digital venture capital platform, Aescuvest.

"This first closure will allow us to continue our international expansion in European markets while completing the second with strategic investors”, explains Markus  Wilhems, CEO and co-founder of MOWOOT.

The closure of the first tranche arrives weeks after the company reached one of its major milestones, the achievement of part of the European Patent Office (EPO) of the European patent. At the end of last year, they obtained patents for the United States and China, in addition to obtaining the designation of Breakthrough  Device Designation (BDD) from the FDA (United States).